Full text is available at the source.
Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon‐like peptide‐1 receptor agonists: A systematic analysis of published clinical trials
Nausea, vomiting, and diarrhea reported as side effects in clinical trials of glucagon-like peptide-1 receptor agonists
AI simplified
Abstract
The risk of nausea from GLP-1 receptor agonists is dose-dependent, with a significance level of P = .0017.
- Nausea and diarrhoea risks increase with higher doses of GLP-1 receptor agonists.
- Background treatment with metformin is linked to higher incidences of nausea and vomiting.
- Lixisenatide shows lower rates of nausea and diarrhoea compared to exenatide b.i.d.
- Dulaglutide has a similar risk of nausea and vomiting as liraglutide, but lower risks with exenatide q.w. and albiglutide.
- Long-acting GLP-1 receptor agonists may lead to less nausea and vomiting but result in more diarrhoea compared to short-acting ones.
AI simplified